Lung CancerPhase 3NCT00032084
S0002 - A Program to Quit Smoking With or Without Bupropion in Treating Patients With Stage I or II Non-Small Cell Lung Cancer Who Have Undergone Surgery
A Phase 3 study testing smoking cessation intervention, bupropion hydrochloride and nicotine in people with Lung Cancer, run by SWOG Cancer Research Network at 176 sites in 2 countries.
Trial summary
RATIONALE: A program that includes bupropion may be more effective in helping early-stage lung cancer patients to quit smoking. It is not yet known if a program to quit smoking is more effective with or without bupropion. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Lung Cancer
- What is being tested?
- smoking cessation intervention, bupropion hydrochloride and nicotine
- Type of treatment
- Surgery or procedure, Lifestyle or therapy programme
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 10 participants
- Where
- 176 sitesin 2 countries
- Study dates
- Jan 2002to Feb 2004
- Phase
- Phase 3
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
DISEASE CHARACTERISTICS:
- Diagnosis of stage I or II non-small cell lung cancer with complete resection of all disease
- Must be free of recurrent or progressive disease
- Current smoker defined as:
- Smoked at least 100 cigarettes in entire life AND
- Currently smoking some days or every day
- Must establish a quit date that falls within 30 days after registration, but 7 days after physician advice and start of bupropion or placebo therapy
PATIENT CHARACTERISTICS:
Age:
- 18 and over
Performance status:
- Zubrod 0-2
Life expectancy:
- Not specified
Hematopoietic:
- Not specified
Hepatic:
- Not specified
Renal:
- Not specified
Cardiovascular:
- Not within an immediate post-infarction period
- No uncontrolled arrhythmias
- No unstable angina
- No uncontrolled hypertension (unstable blood pressure, diastolic pressure 90 mm Hg or greater)
Other:
- Must be able to read, speak, and understand English
- Must be willing to allow testing of saliva for cotinine levels
- No history of seizures
- No history of eating disorders
- No known drug-drug interactions between nicotine patch and/or bupropion and patient's current or planned medications including chemotherapy and antiemetics
- No concurrent psychiatric diagnosis that would preclude study compliance
PRIOR CONCURRENT THERAPY:
Biologic therapy:
- Not specified
Chemotherapy:
- Concurrent adjuvant chemotherapy allowed
Endocrine therapy:
- No concurrent systemic steroids
Radiotherapy:
- Concurrent adjuvant radiotherapy allowed
Surgery:
- See Disease Characteristics
- Recovered from prior surgery
Other:
- Prior neoadjuvant therapy allowed
- At least 14 days since prior medications containing bupropion (e.g., Wellbutrin or Wellbutrin SR)
- No other concurrent medications that contain bupropion (e.g., Wellbutrin or Wellbutrin SR)
- No concurrent monoamine oxidase inhibitors
- No concurrent medications that lower seizure threshold (e.g., antipsychotics, antidepressants, or theophylline)
- No other concurrent nicotine replacement therapy
Trial locations and contacts
176 sites in 2 countries.
176 sites in 2 countries
United States175 sites
Veterans Affairs Medical Center - Albany
Albany, New York, 12208
Veterans Affairs Medical Center - Albuquerque
Albuquerque, New Mexico, 87108-5138
MBCCOP - University of New Mexico HSC
Albuquerque, New Mexico, 87131
Harrington Cancer Center
Amarillo, Texas, 79106
Veterans Affairs Medical Center - Amarillo
Amarillo, Texas, 79106
Veterans Affairs Medical Center - Ann Arbor
Ann Arbor, Michigan, 48105
CCOP - Michigan Cancer Research Consortium
Ann Arbor, Michigan, 48106
University of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan, 48109-0912
Northeast Alabama Regional Medical Center
Anniston, Alabama, 36207
Veterans Affairs Medical Center - Asheville
Asheville, North Carolina, 28805
CCOP - Atlanta Regional
Atlanta, Georgia, 30342-1701
Marlene and Stewart Greenebaum Cancer Center, University of Maryland
Baltimore, Maryland, 21201
Veterans Affairs Medical Center - Baltimore
Baltimore, Maryland, 21201
Green Mountain Oncology Group
Bennington, Vermont, 05201
CCOP - Montana Cancer Consortium
Billings, Montana, 59101
Veterans Affairs Medical Center - Biloxi
Biloxi, Mississippi, 39531-2410
Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute
Boston, Massachusetts, 02115
Cancer Research Center at Boston Medical Center
Boston, Massachusetts, 02118
Veterans Affairs Medical Center - Buffalo
Buffalo, New York, 14215
Vermont Cancer Center at University of Vermont
Burlington, Vermont, 05401-3498
Cooper University Hospital
Camden, New Jersey, 08103
Lineberger Comprehensive Cancer Center, UNC
Chapel Hill, North Carolina, 27599-7295
Veterans Affairs Medical Center - Charleston
Charleston, South Carolina, 29401-5799
Hollings Cancer Center at Medical University of South Carolina
Charleston, South Carolina, 29425
Martha Jefferson Hospital
Charlottesville, Virginia, 22902
MBCCOP - University of Illinois at Chicago
Chicago, Illinois, 60612-7323
Veterans Affairs Medical Center - Chicago (Westside Hospital)
Chicago, Illinois, 60612
University of Chicago Cancer Research Center
Chicago, Illinois, 60637-1470
Louis A. Weiss Memorial Hospital
Chicago, Illinois, 60640
Veterans Affairs Medical Center - Cincinnati
Cincinnati, Ohio, 45220-2288
Charles M. Barrett Cancer Center at University Hospital
Cincinnati, Ohio, 45267-0501
Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio, 44195-9001
Veterans Affairs Medical Center - Columbia (Truman Memorial)
Columbia, Missouri, 65201
Ellis Fischel Cancer Center at University of Missouri - Columbia
Columbia, Missouri, 65203
CCOP - Columbus
Columbus, Ohio, 43206
Arthur G. James Cancer Hospital - Ohio State University
Columbus, Ohio, 43210-1240
NorthEast Oncology Associates
Concord, North Carolina, 28025
Veterans Affairs Medical Center - Dallas
Dallas, Texas, 75216
Veterans Affairs Medical Center - Dayton
Dayton, Ohio, 45428
CCOP - Dayton
Dayton, Ohio, 45429
CCOP - Central Illinois
Decatur, Illinois, 62526
University of Colorado Cancer Center at University of Colorado Health Sciences Center
Denver, Colorado, 80010
Veterans Affairs Medical Center - Denver
Denver, Colorado, 80220
CCOP - Iowa Oncology Research Association
Des Moines, Iowa, 50309-1016
Barbara Ann Karmanos Cancer Institute
Detroit, Michigan, 48201-1379
Veterans Affairs Medical Center - Detroit
Detroit, Michigan, 48201-1932
Josephine Ford Cancer Center at Henry Ford Hospital
Detroit, Michigan, 48202
City of Hope Comprehensive Cancer Center
Duarte, California, 91010
Veterans Affairs Medical Center - Durham
Durham, North Carolina, 27705
Duke Comprehensive Cancer Center
Durham, North Carolina, 27710
Elmhurst Hospital Center
Elmhurst, New York, 11373
Veterans Affairs Medical Center - Fargo
Fargo, North Dakota, 58102
Cape Fear Valley Health System
Fayetteville, North Carolina, 28302-2000
Broward General Medical Center
Fort Lauderdale, Florida, 33316
Brooke Army Medical Center
Fort Sam Houston, Texas, 78234-6200
Fort Wayne Medical Oncology and Hematology, Incorporated
Fort Wayne, Indiana, 46885-5099
University of Texas Medical Branch
Galveston, Texas, 77555-0565
CCOP - Grand Rapids
Grand Rapids, Michigan, 49503
CCOP - St. Vincent Hospital Cancer Center, Green Bay
Green Bay, Wisconsin, 54307-3453
CCOP - Greenville
Greenville, South Carolina, 29615
Veterans Affairs Medical Center - Hines (Hines Junior VA Hospital)
Hines, Illinois, 60141
Memorial Regional Hospital Comprehensive Cancer Center
Hollywood, Florida, 33021
MBCCOP - Hawaii
Honolulu, Hawaii, 96813
University of Texas - MD Anderson Cancer Center
Houston, Texas, 77030-4095
Veterans Affairs Medical Center - Houston
Houston, Texas, 77030
St. Mary's Medical Center
Huntington, West Virginia, 25701
Holden Comprehensive Cancer Center at University of Iowa
Iowa City, Iowa, 52242-1009
University of Mississippi Medical Center
Jackson, Mississippi, 39216-4505
Veterans Affairs Medical Center - Jackson
Jackson, Mississippi, 39216
Queens Cancer Center of Queens Hospital
Jamaica, New York, 11432
Kansas Cancer Institute at the University of Kansas Medical Center
Kansas City, Kansas, 66160-7353
Veterans Affairs Medical Center - Kansas City
Kansas City, Missouri, 64128
CCOP - Kansas City
Kansas City, Missouri, 64131
Lenoir Memorial Hospital Cancer Center
Kinston, North Carolina, 28503-1678
Rebecca and John Moores UCSD Cancer Center
La Jolla, California, 92093-0658
CCOP - Southern Nevada Cancer Research Foundation
Las Vegas, Nevada, 89106
Veterans Affairs Medical Center - Las Vegas
Las Vegas, Nevada, 89106
Norris Cotton Cancer Center at Dartmouth Medical School
Lebanon, New Hampshire, 03756-0002
Veterans Affairs Medical Center - Lexington
Lexington, Kentucky, 40502-2236
Albert B. Chandler Medical Center, University of Kentucky
Lexington, Kentucky, 40536-0084
University of Arkansas for Medical Sciences
Little Rock, Arkansas, 72205
Veterans Affairs Medical Center - Little Rock (McClellan)
Little Rock, Arkansas, 72205
USC/Norris Comprehensive Cancer Center and Hospital
Los Angeles, California, 90033-0804
Cedars-Sinai Comprehensive Cancer Center at Cedars-Sinai Medical Center
Los Angeles, California, 90048
Veterans Affairs Medical Center - West Los Angeles
Los Angeles, California, 90073
Jonsson Comprehensive Cancer Center, UCLA
Los Angeles, California, 90095-1781
Baptist Hospital East - Louisville
Louisville, Kentucky, 40207
CCOP - North Shore University Hospital
Manhasset, New York, 11030
North Shore University Hospital
Manhasset, New York, 11030
CCOP - Marshfield Clinic Research Foundation
Marshfield, Wisconsin, 54449
Veterans Affairs Outpatient Clinic - Martinez
Martinez, California, 94553
Loyola University Medical Center
Maywood, Illinois, 60153-5500
University of Tennessee Cancer Institute
Memphis, Tennessee, 38103
Danville Radiation Therapy Center
Memphis, Tennessee, 38104
CCOP - Mount Sinai Medical Center
Miami Beach, Florida, 33140
Veterans Affairs Medical Center - Minneapolis
Minneapolis, Minnesota, 55417
University of Minnesota Cancer Center
Minneapolis, Minnesota, 55455
MBCCOP - Gulf Coast
Mobile, Alabama, 36688
MBCCOP - LSU Health Sciences Center
New Orleans, Louisiana, 70112
Tulane University School of Medicine
New Orleans, Louisiana, 70112
Veterans Affairs Medical Center - New Orleans
New Orleans, Louisiana, 70112
Memorial Sloan-Kettering Cancer Center
New York, New York, 10021
New York Weill Cornell Cancer Center at Cornell University
New York, New York, 10021
Mount Sinai Medical Center, NY
New York, New York, 10029
Herbert Irving Comprehensive Cancer Center at Columbia University
New York, New York, 10032
CCOP - Christiana Care Health Services
Newark, Delaware, 19713
Virginia Oncology Associates - Norfolk
Norfolk, Virginia, 23502
CCOP - Bay Area Tumor Institute
Oakland, California, 94609-3305
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma, 73104
Veterans Affairs Medical Center - Oklahoma City
Oklahoma City, Oklahoma, 73104
University of Nebraska Medical Center
Omaha, Nebraska, 68198-7680
Chao Family Comprehensive Cancer Center at University of California Irvine Cancer Center
Orange, California, 92868
Florida Hospital Cancer Institute
Orlando, Florida, 32804
CCOP - Western Regional, Arizona
Phoenix, Arizona, 85006-2726
Veterans Affairs Medical Center - Phoenix (Carl T. Hayden)
Phoenix, Arizona, 85012
FirstHealth Moore Regional Hospital
Pinehurst, North Carolina, 28374
Western Pennsylvania Hospital
Pittsburgh, Pennsylvania, 15224
Cancer Institute at Oregon Health and Science University
Portland, Oregon, 97201-3098
Veterans Affairs Medical Center - Portland
Portland, Oregon, 97207
CCOP - Columbia River Oncology Program
Portland, Oregon, 97225
Lifespan: The Miriam Hospital
Providence, Rhode Island, 02906
Ministry Medical Group - Northern Region
Rhinelander, Wisconsin, 54501
MBCCOP - Massey Cancer Center
Richmond, Virginia, 23298-0037
West Suburban Center for Cancer Care
River Forest, Illinois, 60305
Oncology and Hematology Associates of Southwest Virginia, Inc.
Roanoke, Virginia, 24014
Mayo Clinic Cancer Center
Rochester, Minnesota, 55905
James P. Wilmot Cancer Center at University of Rochester Medical Center
Rochester, New York, 14642
Saint Anthony Medical Center
Rockford, Illinois, 61108
CCOP - Beaumont
Royal Oak, Michigan, 48073-6769
University of California Davis Cancer Center
Sacramento, California, 95817
Lakeland Medical Center - St. Joseph
Saint Joseph, Michigan, 49085
Huntsman Cancer Institute
Salt Lake City, Utah, 84112-5550
Veterans Affairs Medical Center - Salt Lake City
Salt Lake City, Utah, 84148
University of Texas Health Science Center at San Antonio
San Antonio, Texas, 78229-3900
Veterans Affairs Medical Center - San Antonio (Murphy)
San Antonio, Texas, 78229
Veterans Affairs Medical Center - San Diego
San Diego, California, 92161
UCSF Comprehensive Cancer Center
San Francisco, California, 94115
Veterans Affairs Medical Center - San Francisco
San Francisco, California, 94121
CCOP - Santa Rosa Memorial Hospital
Santa Rosa, California, 95403
CCOP - Virginia Mason Research Center
Seattle, Washington, 98101
Veterans Affairs Medical Center - Seattle
Seattle, Washington, 98108
Louisiana State University Health Sciences Center - Shreveport
Shreveport, Louisiana, 71130-3932
Veterans Affairs Medical Center - Shreveport
Shreveport, Louisiana, 71130
CCOP - Northern Indiana CR Consortium
South Bend, Indiana, 46601
Providence Hospital - Southfield
Southfield, Michigan, 48075-9975
CCOP - Upstate Carolina
Spartanburg, South Carolina, 29303
CCOP - Cancer Research for the Ozarks
Springfield, Missouri, 65807
Barnes-Jewish Hospital
St Louis, Missouri, 63110
St. Louis University Health Sciences Center
St Louis, Missouri, 63110
Missouri Baptist Cancer Center
St Louis, Missouri, 63131
CCOP - St. Louis-Cape Girardeau
St Louis, Missouri, 63141
State University of New York - Upstate Medical University
Syracuse, New York, 13210
Veterans Affairs Medical Center - Syracuse
Syracuse, New York, 13210
CCOP - Syracuse Hematology-Oncology Associates of Central New York, P.C.
Syracuse, New York, 13217
CCOP - Northwest
Tacoma, Washington, 98405-0986
Madigan Army Medical Center
Tacoma, Washington, 98431-5000
Veterans Affairs Medical Center - Temple
Temple, Texas, 76504
CCOP - Scott and White Hospital
Temple, Texas, 76508
David Grant Medical Center
Travis Air Force Base, California, 94535
Veterans Affairs Medical Center - Tucson
Tucson, Arizona, 85723
Arizona Cancer Center at University of Arizona Health Sciences Center
Tucson, Arizona, 85724
CCOP - Carle Cancer Center
Urbana, Illinois, 61801
Lombardi Cancer Center of Georgetown University Medical Center
Washington D.C., District of Columbia, 20007
MBCCOP - Howard University Cancer Center
Washington D.C., District of Columbia, 20060
Walter Reed Army Medical Center
Washington D.C., District of Columbia, 20307-5000
Veterans Affairs Medical Center - Washington, DC
Washington D.C., District of Columbia, 20422
Palm Beach Cancer Institute
West Palm Beach, Florida, 33401
Veterans Affairs Medical Center - White River Junction
White River Junction, Vermont, 05009
CCOP - Wichita
Wichita, Kansas, 67214-3882
Veterans Affairs Medical Center - Wichita
Wichita, Kansas, 67218
New Hanover Regional Medical Center
Wilmington, North Carolina, 28402-9025
CCOP - Southeast Cancer Control Consortium
Winston-Salem, North Carolina, 27104-4241
Comprehensive Cancer Center at Wake Forest University
Winston-Salem, North Carolina, 27157-1082
University of Massachusetts Memorial Medical Center - University Campus
Worcester, Massachusetts, 01655
CCOP - MainLine Health
Wynnewood, Pennsylvania, 19096
Puerto Rico1 site
University of Puerto Rico School of Medicine Medical Sciences Campus
San Juan, 00936-5067
About this study
Official title: Smoking Cessation Intervention (Including Bupropion-Zyban Versus Placebo) for Completely Resected Stage I and II Non-Small Cell Lung Cancer Survivors Who Are Current Smokers
RATIONALE: A program that includes bupropion may be more effective in helping early-stage lung cancer patients to quit smoking. It is not yet known if a program to quit smoking is more effective with or without bupropion.
PURPOSE: Randomized phase III trial to determine the effectiveness of a program to quit smoking with or without bupropion in treating patients who have undergone surgery for stage I or stage II non-small cell lung cancer.
Read the detailed description
OBJECTIVES:
- Compare the effect of a smoking cessation intervention comprising behavior intervention and nicotine replacement with or without bupropion on 12-month quit rates in patients with completely resected stage I or II non-small cell lung cancer who are current smokers.
- Compare the predictors of smoking cessation success in patients treated with these regimens.
- Determine the relationship between smoking cessation and standard outcome measures (e.g., second malignancies, survival, and symptom status) in patients treated with these regimens.
- Compare the effect of these treatment regimens on emotional functioning in these patients.
OUTLINE: This is a randomized, double-blind, multicenter study. Patients are stratified according to gender, prior neoadjuvant or concurrent adjuvant chemotherapy and/or radiotherapy (yes vs no), and time since prior surgery (less than 6 months vs 6 to 12 months vs more than 12 months). Patients are randomized to 1 of 2 arms.
All patients receive behavioral intervention comprising smoking cessation advice and education on day 1. Patients quit smoking on day 8. Patients then receive a nicotine transdermal patch once daily on days 8-77.
- Arm I: Patients receive oral bupropion once daily on days 1-3 and twice daily on days 4-77.
- Arm II: Patients receive oral placebo as in arm I. Patients are followed at 3, 6, and 12 months and then annually for 10 years.
PROJECTED ACCRUAL: A total of 468 patients (234 [117 men and 117 women] per arm) will be accrued for this study within 3 years.
- Conditions
- Lung Cancer
- Being tested
- smoking cessation intervention, bupropion hydrochloride, nicotine, psychosocial assessment and care
- Keywords
- non-small cell lung cancer, stage I non-small cell lung cancer, stage II non-small cell lung cancer
- Medical subject headings
- Lung Neoplasms, Carcinoma, Non-Small-Cell Lung
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
smoking cessation interventionBehavioural
Physician will deliver the smoking cessation advice, reinforce the established quit date (no sooner than seven days after starting bupropion/placebo), and will distribute patient educational materials and all pharmacotherapy
bupropion hydrochlorideDrug
Also called Zyban
150 mg/day on Days 1-3, 300 mg/day on Day 4-77
nicotineDrug
Also called Nicoderm CQ
21 mg patch/day for Weeks 2-7; 14 mg patch/day for Weeks 8-9; 7 mg patch/day for Weeks 10-11.
psychosocial assessment and careProcedure or surgery
The nurse/CRA will debrief the patients after the brief physician intervention and will follow-up with a series of 5 phone calls to provide booster advice. All advice will be based on the stage of change model (i.e., tailored to the patient's readiness to quit and/or stay off cigarettes).
| Study group | Role | What they receive |
|---|---|---|
| Behavioral Intervention + Placebo | Placebo comparator | Smoking cessation intervention , nicotine replacement, psychosocial assessment and care, and placebo. Receives: Behavioral: smoking cessation intervention; Drug: nicotine; Procedure: psychosocial assessment and care |
| Behavioral Intervention + Bupropion | Active comparator | Smoking cessation intervention, nicotine replacement, psychosocial assessment and care, and bupropion hydrochloride . Receives: Behavioral: smoking cessation intervention; Drug: bupropion hydrochloride; Drug: nicotine; Procedure: psychosocial assessment and care |
What is being measured
The primary outcome is the main question the study is designed to answer.
To compare the effect on 12 month quit rates of adding an anti-depressant versus placebo in a double blind to an intervention and nicotine replacement in complete resected Stage I and II non-small cell lung cancer patients who are current smokers
Measured: 12 months
Secondary outcomes (3)
To assess predictors of successful cessation in male and female patients.
Measured: 12 months
To explore the relationship between smoking cessation and standard outcome measures.
Measured: 12 months
To compare the effect on emotional functioning of adding bupropion to a behavioral intervention plus nicotine replacement in this patient population.
Measured: 12 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted27 Jan 2003 (estimated)
- Study startJan 2002
- Primary completionFeb 2004
- Study completionFeb 2004
Why it stopped: This study was closed early due to poor accrual
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Lung CancerStudies of the same condition, open and under way.
- More trials run by SWOG Cancer Research NetworkThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 10 participants (actual)
Sponsor and investigators
- Lead sponsor
- SWOG Cancer Research Network
- Sponsor type
- Research network
- Collaborators
- National Cancer Institute (NCI), Cancer and Leukemia Group B, Eastern Cooperative Oncology Group
- Responsible party
- Sponsor
- Investigators
- Ellen R. Gritz, PhD, Study chair, M.D. Anderson Cancer CenterPhilip C. Hoffman, MD, Study chair, University of ChicagoJames Stevenson, MD, Study chair, Presbyterian medical center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00032084
- Sponsor's protocol ID
- CDR0000069256
- Other IDs
- SWOG-S0002, CALGB-79807, ECOG-S0002, NCI-P02-0215
- Status last verified
- Mar 2013
- First submitted
- 8 Mar 2002
- Last updated
- 11 Mar 2013
- Results posted
- No
- Data monitoring committee
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 11 Mar 2013. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Smoking Cessation Intervention (Including Bupropion-Zyban Versus Placebo) for Completely Resected Stage I and II Non-Small Cell Lung Cancer Survivors Who Are Current Smokers
- ClinicalTrials.gov ID
- NCT00032084
- Acronym / sponsor ID
- CDR0000069256
- Conditions
- Lung Cancer
- Keywords
- non-small cell lung cancer, stage I non-small cell lung cancer, stage II non-small cell lung cancer
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- TerminatedReason stopped: This study was closed early due to poor accrual
- Enrolment
- 10 participants (actual)
- Lead sponsor
- SWOG Cancer Research NetworkResearch network
- Collaborators
- National Cancer Institute (NCI), Cancer and Leukemia Group B, Eastern Cooperative Oncology Group
- Study start
- Jan 2002
- Primary completion
- Feb 2004 (actual)
- Study completion
- Feb 2004 (actual)
- First posted
- 27 Jan 2003 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
RATIONALE: A program that includes bupropion may be more effective in helping early-stage lung cancer patients to quit smoking. It is not yet known if a program to quit smoking is more effective with or without bupropion.
PURPOSE: Randomized phase III trial to determine the effectiveness of a program to quit smoking with or without bupropion in treating patients who have undergone surgery for stage I or stage II non-small cell lung cancer.
Detailed description
OBJECTIVES:
- Compare the effect of a smoking cessation intervention comprising behavior intervention and nicotine replacement with or without bupropion on 12-month quit rates in patients with completely resected stage I or II non-small cell lung cancer who are current smokers.
- Compare the predictors of smoking cessation success in patients treated with these regimens.
- Determine the relationship between smoking cessation and standard outcome measures (e.g., second malignancies, survival, and symptom status) in patients treated with these regimens.
- Compare the effect of these treatment regimens on emotional functioning in these patients.
OUTLINE: This is a randomized, double-blind, multicenter study. Patients are stratified according to gender, prior neoadjuvant or concurrent adjuvant chemotherapy and/or radiotherapy (yes vs no), and time since prior surgery (less than 6 months vs 6 to 12 months vs more than 12 months). Patients are randomized to 1 of 2 arms.
All patients receive behavioral intervention comprising smoking cessation advice and education on day 1. Patients quit smoking on day 8. Patients then receive a nicotine transdermal patch once daily on days 8-77.
- Arm I: Patients receive oral bupropion once daily on days 1-3 and twice daily on days 4-77.
- Arm II: Patients receive oral placebo as in arm I. Patients are followed at 3, 6, and 12 months and then annually for 10 years.
PROJECTED ACCRUAL: A total of 468 patients (234 [117 men and 117 women] per arm) will be accrued for this study within 3 years.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Behavioral Intervention + Placebo | Placebo comparator | Behavioral: smoking cessation intervention, Drug: nicotine, Procedure: psychosocial assessment and careSmoking cessation intervention , nicotine replacement, psychosocial assessment and care, and placebo. |
| Behavioral Intervention + Bupropion | Active comparator | Behavioral: smoking cessation intervention, Drug: bupropion hydrochloride, Drug: nicotine, Procedure: psychosocial assessment and careSmoking cessation intervention, nicotine replacement, psychosocial assessment and care, and bupropion hydrochloride . |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| smoking cessation interventionPhysician will deliver the smoking cessation advice, reinforce the established quit date (no sooner than seven days after starting bupropion/placebo), and will distribute patient educational materials and all pharmacotherapy | Behavioural | Behavioral Intervention + Bupropion, Behavioral Intervention + Placebo |
| bupropion hydrochlorideAlso: Zyban150 mg/day on Days 1-3, 300 mg/day on Day 4-77 | Drug | Behavioral Intervention + Bupropion |
| nicotineAlso: Nicoderm CQ21 mg patch/day for Weeks 2-7; 14 mg patch/day for Weeks 8-9; 7 mg patch/day for Weeks 10-11. | Drug | Behavioral Intervention + Bupropion, Behavioral Intervention + Placebo |
| psychosocial assessment and careThe nurse/CRA will debrief the patients after the brief physician intervention and will follow-up with a series of 5 phone calls to provide booster advice. All advice will be based on the stage of change model (i.e., tailored to the patient's readiness to quit and/or stay off cigarettes). | Procedure or surgery | Behavioral Intervention + Bupropion, Behavioral Intervention + Placebo |
Primary outcome
To compare the effect on 12 month quit rates of adding an anti-depressant versus placebo in a double blind to an intervention and nicotine replacement in complete resected Stage I and II non-small cell lung cancer patients who are current smokers
Time frame: 12 months
3 secondary outcomes
To assess predictors of successful cessation in male and female patients.
Time frame: 12 months
To explore the relationship between smoking cessation and standard outcome measures.
Time frame: 12 months
To compare the effect on emotional functioning of adding bupropion to a behavioral intervention plus nicotine replacement in this patient population.
Time frame: 12 months
Results and safety
The study was stopped early (reason given: This study was closed early due to poor accrual). Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 11 Mar 2013.
Related trials for Lung Cancer
Recruiting
MRD-Guided Postoperative Surveillance and Adaptive Treatment for Resectable Lung Cancer
Lung Neoplasms, Neoadjuvant Therapy
Not yet recruitingPhase 3
Intraarterial Therapies Plus Tislelizumab Plus Lenvatinib Versus Tislelizumab Plus Gemcitabine-Cisplatin in Unresectable Intrahepatic Cholangiocarcinoma
Intrahepatic Cholangiocarcinoma (Icc)
Active, not recruitingPhase 3
A Study to Compare the Efficacy, Safety, Pharmacokinetics, and Immunogenicity Between SB27 and Keytruda in Subjects With Metastatic Non-squamous Non-small Cell Lung Cancer
Non-small Cell Lung Cancer Stage IV
RecruitingObservational study
Label-free Femtosecond Laser Imaging Combined With the Fast Lung Artificial Intelligence Model for Rapid Intraoperative Diagnosis of Lung Surgical Specimens: A Multicentre, Prospective, Parallel-workflow, Non-inferiority Study.
Lung Cancer
RecruitingPhase 3
A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
Non-small Cell Lung Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Ellen R. Gritz, PhD study chair
M.D. Anderson Cancer Center
Philip C. Hoffman, MD study chair
University of Chicago
James Stevenson, MD study chair
Presbyterian medical center
176 sites in 2 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing smoking cessation intervention, bupropion hydrochloride and nicotine in people with Lung Cancer, run by SWOG Cancer Research Network at 176 sites in 2 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: stopped early, as of the sponsor's last update on 11 Mar 2013. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 176 sites in United States, Puerto Rico. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study was stopped early (reason given: This study was closed early due to poor accrual). Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
To compare the effect on 12 month quit rates of adding an anti-depressant versus placebo in a double blind to an intervention and nicotine replacement in complete resected Stage I and II non-small cell lung cancer patients who are current smokers (time frame: 12 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 Mar 2013.